334 related articles for article (PubMed ID: 26523780)
21. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
Dutoit V; Taub RN; Papadopoulos KP; Talbot S; Keohan ML; Brehm M; Gnjatic S; Harris PE; Bisikirska B; Guillaume P; Cerottini JC; Hesdorffer CS; Old LJ; Valmori D
J Clin Invest; 2002 Dec; 110(12):1813-22. PubMed ID: 12488431
[TBL] [Abstract][Full Text] [Related]
22. The E75 HER2/neu peptide vaccine.
Mittendorf EA; Holmes JP; Ponniah S; Peoples GE
Cancer Immunol Immunother; 2008 Oct; 57(10):1511-21. PubMed ID: 18536917
[TBL] [Abstract][Full Text] [Related]
23. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.
Carmichael MG; Benavides LC; Holmes JP; Gates JD; Mittendorf EA; Ponniah S; Peoples GE
Cancer; 2010 Jan; 116(2):292-301. PubMed ID: 19924797
[TBL] [Abstract][Full Text] [Related]
24. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.
Perez SA; Sotiropoulou PA; Sotiriadou NN; Mamalaki A; Gritzapis AD; Echner H; Voelter W; Pawelec G; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2002 Jan; 50(11):615-24. PubMed ID: 11807625
[TBL] [Abstract][Full Text] [Related]
25. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
Benavides LC; Sears AK; Gates JD; Clifton GT; Clive KS; Carmichael MG; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2011 Feb; 10(2):201-10. PubMed ID: 21332269
[TBL] [Abstract][Full Text] [Related]
26. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
27. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
Tanaka Y; Amos KD; Fleming TP; Eberlein TJ; Goedegebuure PS
Surgery; 2003 Jan; 133(1):74-80. PubMed ID: 12563241
[TBL] [Abstract][Full Text] [Related]
28. Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.
Harao M; Mittendorf EA; Radvanyi LG
BioDrugs; 2015 Feb; 29(1):15-30. PubMed ID: 25523015
[TBL] [Abstract][Full Text] [Related]
29. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
31. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.
Wiedermann U; Davis AB; Zielinski CC
Breast Cancer Res Treat; 2013 Feb; 138(1):1-12. PubMed ID: 23340862
[TBL] [Abstract][Full Text] [Related]
32. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
33. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Peoples GE; Holmes JP; Hueman MT; Mittendorf EA; Amin A; Khoo S; Dehqanzada ZA; Gurney JM; Woll MM; Ryan GB; Storrer CE; Craig D; Ioannides CG; Ponniah S
Clin Cancer Res; 2008 Feb; 14(3):797-803. PubMed ID: 18245541
[TBL] [Abstract][Full Text] [Related]
34. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Amin A; Benavides LC; Holmes JP; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Storrer CE; Jama YH; Craig D; Stojadinovic A; Ponniah S; Peoples GE
Cancer Immunol Immunother; 2008 Dec; 57(12):1817-25. PubMed ID: 18392824
[TBL] [Abstract][Full Text] [Related]
35. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
36. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
Front Immunol; 2018; 9():776. PubMed ID: 29867922
[TBL] [Abstract][Full Text] [Related]
37. Immunizing against breast cancer: a new swing for an old sword.
Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A
Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543
[TBL] [Abstract][Full Text] [Related]
38. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
